Assessment of preoperative noninvasive ventilation before lung cancer surgery: The preOVNI randomized controlled study

 

J Thorac Cardiovasc Surg. 2019 Nov 23. pii: S0022-5223(19)33106-X

 

Lien : 10.1016/j.jtcvs.2019.09.193

 

Paleiron N, Grassin F, Lancelin C, Tromeur C, Margery J, Natale C, Couturaud F; GFPC Group.

 

 

Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer.

 

BMC Cancer 2019 Dec 19;19(1):1237.

 

Lien : 10.1186/s12885-019-6449-8

 

Kissel M, Martel-Lafay I, Lequesne J, Faivre JC, Le Péchoux C, Stefan D, Barraux V, Loiseau C, Grellard JM, Danhier S, Lerouge D, Chouaid C, Gervais R, Thariat J.

 

 

 

French Lung Cancer Group Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01).

 

Cancer Manag Res. 2019 Dec 27;11:10821-10826.

 

Lien: 10.2147/CMAR.S219984

 

Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I;

 

 

 

Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.

 

Clin Cancer Res. 2019;25:5759-5765

 

Lien: 10.1158/1078-0432.CCR-18-2860

 

Eberst G, Anota A, Scherpereel A, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Léna H, Rivière F, Monnet I, Gounant V, Janicot H, Gervais R, Locher C, Charton E, Morin F, Zalcman G, Westeel V; French Cooperative Thoracic Intergroup (IFCT).

 

 

 

Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).

 

Cancer Med. 2019 Nov 20

 

Lien : 10.1002/cam4.2716

 

Vergnenegre A, Geier M, Guisier F, Lamy R, Comet B, Le Garff G, Do P, Janicot H, Morel H, Decroisette C, Andre M, Falchero L, Paleiron N, Monnet I; GFPC Team

 

 

 

Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.

  

J Thorac Oncol. 2019 Feb;14(2):304-310.

 

Lien : 10.1016/j.jtho.2018.10.168

 

Karachaliou N, Bracht JWP, Fernandez Bruno M, Drozdowskyj A, Gimenez Capitan A, Moran T, Carcereny E, Cobo M, Domine M, Chaib I, Ramirez JL, Camps C, Provencio M, Vergnenegre A, Lopez-Vivanco G, Majem M, Massuti B, Rosell R.

 

 

 

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).

 

Lung Cancer.2019 Oct;136:109-114.

 

Lien :  10.1016/j.lungcan.2019.08.010

 

Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Dô P, Schott R, Dansin E, Arrondeau J, Auliac JB, Chouaid C.

 

 

 

Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care.

 

BMJ Support Palliat Care. 2019 Aug 31.

 

Lien : 10.1136/bmjspcare-2019-001770

 

Bylicki O, Didier M, Riviere F, Margery J, Grassin F, Chouaid C.

 

 

 

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.

 

Arthritis Rheumatol. 2019 Dec;71(12):2100-2111.

 

Lien : 10.1002/art.41068

 

Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations.

 

 

 

Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14.

  

2019 Aug;36(8):2161-2166.

 

Lien : 10.1007/s12325-019-01001-9

  

Auliac JB, Dô P, Bayle S, Doubre H, Vinas F, Letreut J, Falchero L, Hauss PA, Thomas P, Chouaid C. Adv Ther.

 

 

 

Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer.

 

Target Oncol. 2019 Jun;14(3):307-314. doi: 10.1007/s11523-019-00646-4

 

Lien : 10.1007/s11523-019-00646-4

 

Auliac JB, Saboundji K, Andre M, Madelaine J, Quere G, Masson P, Vergnenegre A, Lamy R, Raymond S, Chiappa AM, Hauss PA, Fournel P, Corre R, Chouaid C..

 

 

 

Lung cancer survivors and employment: A systematic review Lung Cancer.

  

2019 May;131:31-39.

 

Lien : 10.1016/j.lungcan.2019.03.010

 

Vayr F, Savall F, Bigay-Game L, Soulat JM, Chouaid C, Herin F.

 

 

 

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.

 

BioDrugs.2019 Apr;33(2):159-171.

 

Lien : 10.1007/s40259-019-00339-4

 

Bylicki O, Barazzutti H, Paleiron N, Margery J, Assié JB, Chouaïd C.

 

 

 

Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.

 

Lung Cancer.2019 Jan;127:96-102.

 

Lien : 10.1016/j.lungcan.2018.11.037

 

Auliac JB, Pérol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gerinière L, Renault A, Daniel C, Falchero L, Chouaid C.

 

 

 

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

 

Curr Oncol. 2018 Oct;25(5):e398-e402.

 

Lien : 10.3747/co.25.3945

 

Auliac JB, Bayle S, Vergnenegre A, Le Caer H, Falchero L, Gervais R, Doubre H, Vinas F, Marin B, Chouaid C.

 

 

 

Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.

 

Cancer Med. 2018 Nov;7(11):5505-5513.

 

Lien : 10.1002/cam4.1825

 

Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R.

 

 

 

Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France.

 

Oncology. 2018;95(6):337-343.29.

 

Lien : 10.1159/000489784

 

Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Mazières J, Colineaux H, Lepage B, Chouaid C; GFPC Investigators.

 

 

 

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review.

 

Expert Rev Anticancer Ther. 2018 Nov;18(11):1159-1165.

 

Lien : 10.1080/14737140.2018.1518714

 

Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C.

 

 

 

Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.

 

Target Oncol. 2018;13(4):501-507.

 

Lien : 10.1007/s11523-018-0581-2

 

Saboundji K, Auliac JB, Pérol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaïd C.

 

 

 

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab.

 

Onco Targets Ther. 2018 Jul 16;11:4051-4064.

 

Lien : 10.2147/OTT.S154606

 

Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaïd C.

 

 

 

Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review.

 

Expert Rev Anticancer Ther. 2018 Oct;18(10):981-989.

 

Lien : 10.1080/14737140.2018.1499468

 

Babey H, Quéré G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum JB, Cornec D, Tison A, Chouaid C.

 

 

 

Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).

 

Expert Rev Pharmacoecon Outcomes Res. 2018 Oct;18(5):519-528.

 

Lien :  10.2165/00019053-200927020-00003

 

Vergnenègre A, Chouaïd C.

 

 

 

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).

 

Lung Cancer. 2018 Jul;121:25-29.

 

Lien : 10.1016/j.lungcan.2018.04.017

 

Locher C, Pourel N, Le Caer H, Berard H, Auliac JB, Monnet I, Descourt R, Vergnenègre A, Lafay IM, Greillier L, Chouaïd C.

 

 

 

 

Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study).

 

Oncotarget. 2018 Jan 2;9(9):8253-8262.

 

Lien : 10.18632/oncotarget.23836

 

Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac JB.